FOR US POSTAL SERVICE DELIVERY: Office for Human Research Protections

6100 Executive Boulevard, Suite 3B01 National Institutes of Health (MSC 7507) Rockville, Maryland 20892-7507 FOR HAND DELIVERY OR EXPRESS MAIL:

Office for Human Research Protections 6100 Executive Boulevard, Suite 3B01 Rockville, Maryland 20852

> Telephone: 301-402-5567 FAX: 301-402-2071 E-mail: mc2a@nih.gov

December 4, 2000

George R. Newkome, Ph.D. Vice President for Research University of South Florida 4202 East Fowler Avenue, ADM 200 Tampa, Florida 33620-5950

RE: Human Research Subject Protections Under Multiple Project Assurance (MPA) M-1284

Research Projects: Studies Involving the Tampa Trephine Penetrating Keratoplasty

Procedure for Corneal Transplantation

Principal Investigator: J. James Rowsey, M.D.

Dear Dr. Newkome:

The Office for Human Research Protections (OHRP) has reviewed your November 30, 2000 letter regarding the University of South Florida's (USF's) revised procedures for contacting all surviving subjects (or the parents or legal guardians of children who were subjects) who participated in the above referenced research and informing them of their previous unwitting participation in the research, the risks associated with the research, and the nature of the noncompliance by USF with the requirements of the Department of Health and Human Services (HHS) regulations at 45 CFR Part 46.

OHRP finds that the proposed procedure for contacting and debriefing the subjects that has been approved by the USF IRB-01 is acceptable. OHRP concurs with implementation of this procedure.

By January 19, 2001, please submit to OHRP a progress report on USF's implementation of this debriefing procedure. Please include with your report a copy of one of the signed and dated final letters for each of the four groups of patients to be debriefed (with redaction of patient names and addresses).

Page 2 of 2 University of South Florida - George R. Newkome, Ph.D. December 4, 2000

OHRP appreciates the continued commitment of your institution to the protection of human research subjects. Please do not hesitate to contact me should you have any questions.

Sincerely,

Michael A. Carome, M.D.

Director, Division of Compliance Oversight

cc: Dr. Barry B. Bercu, Chairperson, IRB-01/02, USF

Dr. Martin Klemperer, Chairperson, IRB-03, USF

Dr. William B. Webster, Chairperson, IRB-04, USF

Dr. J. James Rowsey

Commissioner, FDA

Dr. David Lepay, FDA

Dr. James F. McCormack, FDA

Dr. Robert Fish, FDA

Mr. Timothy J. Couzins, FDA

Dr. John Mather, Office of Research Compliance and Assurance, Department of Veterans Affairs

Dr. Susan Rose, Department of Energy

Dr. Greg Koski, OHRP

Dr. Melody H. Lin, OHRP

Dr. J. Thomas Puglisi, OHRP

Dr. Clifford C. Scharke, OHRP

Dr. Katherine Duncan, OHRP

Mr. George Gasparis, OHRP

Dr. Jeffrey M. Cohen, OHRP

Mr. Barry Bowman, OHRP